Pavone-Macaluso M, Lund F, Mulder J H, Smith P H, De Pauw M, Sylvester R
Scand J Urol Nephrol Suppl. 1980;55:163-8.
Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial, and Stilboestrol versus Estracyt in the second trial. Although the follow up is still short, no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant side effects apart from gynaecomastia. In the third trial, patients with advanced disease no longer responsive to hormonal treatment were randomized to either Adriamycin or Procarbazine. Toxicity and early death were particularly frequent in Procarbazine treated patients, whereas most patients progressed in both treatment groups.
欧洲癌症研究与治疗组织泌尿学小组针对既往未接受过治疗的前列腺癌患者开展了两项平行的前瞻性随机研究。在第一项试验中，比较低剂量己烯雌酚、醋酸环丙孕酮和醋酸甲羟孕酮；在第二项试验中，比较己烯雌酚和癌腺治。尽管随访时间仍较短，但就客观反应或除乳腺增生外的显著副作用而言，目前尚未发现其他药物优于己烯雌酚。在第三项试验中，对激素治疗不再有反应的晚期疾病患者被随机分为接受阿霉素或丙卡巴肼治疗。丙卡巴肼治疗的患者毒性反应和早期死亡尤为常见，而两个治疗组的大多数患者病情都出现了进展。
